{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-307450","form_type":"8-K","ticker":"MPLT","cik":"0001770069","company_name":"MapLight Therapeutics, Inc.","filed_at":"2025-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.372343+00:00","generated_at":"2026-05-16T14:51:55.425695+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MapLight reports Q3 net loss $29.4M; cash runway through 2027; Phase 2 readouts in 2026-2027","bullets":["Net loss $29.4M vs $19.0M in Q3 2024; R&D spend $27.1M (up 61% YoY) on clinical trial costs.","Cash & investments $227.2M at Q3 end; Oct IPO netted $269.8M, extending runway through 2027.","Phase 2 ZEPHYR (schizophrenia, n=300) topline H2 2026; VISTA (Alzheimer's psychosis) topline H2 2027.","ML-004 (autism) IRIS Phase 2 enrollment completed (~160 pts); topline results H2 2026.","ML-021 (Parkinson's) IND-enabling studies H2 2026; ML-009 (GPR52 PAM) candidate nominated."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-307450","json":"https://secwatch.observer/filing/0001193125-25-307450.json","markdown":"https://secwatch.observer/filing/0001193125-25-307450.md","text":"https://secwatch.observer/filing/0001193125-25-307450.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/0001193125-25-307450-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/mplt-20251204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:51:55.425695+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}